Nanotechnology-Based Strategies for the Management of COVID-19: Recent Developments and Challenges

COVID-19 is a respiratory disease caused by a newly identified coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since its inception in late December 2019, COVID-19 has led to a tremendous loss of human life worldwide. To overcome the unprecedented challenges posed by the COVID-19 pandemic to the public and economic health, strengthening the healthcare system is of utmost need. In this regard, research communities are putting efforts into developing an advanced healthcare system that could reduce the severe impacts of this pandemic. Nanotechnology is an advanced technology that has contributed significantly to produce powerful arsenals for the frontline warriors in this battle against COVID-19. It has offered opportunities for the development of fast and accurate point-of-care testing, efficient therapeutics and vaccines, potent sanitizers, facemasks, and personal protective equipment against SARS-CoV-2. However, associated toxicity, lengthy procedures of clinical trials, and uncertain health risks are some points that are still debatable. The present paper provides an overview of COVID-19 specific therapeutics and vaccines with an emphasis on nano-based strategies, which are significantly contributing towards the success of mitigation measures and strategies against COVID-19. Furthermore, the associated challenges, current limitations, and opportunities in this field are discussed.

Automated summary

COVID-19, caused by SARS-CoV-2, has resulted in global human fatalities and has posed unprecedented challenges. Nanotechnology has played a crucial role in producing protective equipment and medicines against this pandemic. However, issues such as toxicity, clinical trials, and health risks remain debatable.